Farah Ghori Javed, MD
Endocrinology, Diabetes & Metabolism · Birmingham, ALNPI 1073807871
Payments from drug & device makers
Across 455 payments — averaging $18.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$962
- Bayer$850
- Xeris Pharmaceuticals, Inc.$716
- Corcept Therapeutics$704
- Abbott$657
- plus $4K from 31 others
What the payments were for
- Food & beverage$8,413100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 64 | $1,019 |
| Novo Nordisk | 48 | $962 |
| Bayer | 48 | $850 |
| Xeris Pharmaceuticals, Inc. | 40 | $716 |
| Corcept Therapeutics | 35 | $704 |
| Abbott | 34 | $657 |
| AstraZeneca(2 entities) | 28 | $512 |
| Dexcom, Inc. | 25 | $495 |
| Novartis | 26 | $443 |
| Sanofi-aventis U.S. LLC | 21 | $384 |
| AbbVie | 11 | $185 |
| IBSA Pharma Inc. | 7 | $126 |
| Boehringer Ingelheim | 7 | $123 |
| Medtronic(2 entities) | 6 | $120 |
| BETA Bionics, Inc. | 4 | $108 |
| Kyowa Kirin, Inc. | 5 | $103 |
| Amneal Pharmaceuticals LLC | 6 | $99 |
| Tandem Diabetes Care, Inc. | 4 | $82 |
| Insulet Corporation | 4 | $65 |
| Soleno Therapeutics, Inc. | 3 | $64 |
| Amgen | 3 | $60 |
| Amarin Pharma, Inc. | 3 | $57 |
| Shire North American Group Inc | 3 | $56 |
| Halozyme Inc | 2 | $44 |
| GSK | 2 | $42 |
| Antares Pharma, Inc. | 2 | $40 |
| Recordati_rare_diseases_inc. | 2 | $40 |
| Ascendis Pharma Endocrinology Inc | 2 | $39 |
| Radius Health, Inc. | 1 | $33 |
| Rhythm Pharmaceuticals, Inc. | 2 | $32 |
| Madrigal Pharmaceuticals | 1 | $30 |
| Nevro Corp. | 1 | $27 |
| Chiesi USA, Inc. | 1 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| Averitas Pharma Inc. | 1 | $24 |
| Amphastar Pharmaceuticals, Inc. | 1 | $17 |
| Mannkind Corporation | 1 | $15 |
How this compares
$8,425 in reported general payments places this provider in the 55th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 320 | $361,633 |
| OzempicSemaglutide | 193 | $208,418 |
| FarxigaDapagliflozin Propanediol | 167 | $127,365 |
| JardianceEmpagliflozin | 109 | $83,628 |
| ProliaDenosumab | 26 | $44,701 |
| Tresiba Flextouch U-100Insulin Degludec | 70 | $43,001 |
| RybelsusSemaglutide | 38 | $36,092 |
| KerendiaFinerenone | 40 | $32,438 |
| LyumjevInsulin Lispro-Aabc | 20 | $27,902 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $26,496 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 49 | $25,806 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $22,269 |
| JanuviaSitagliptin Phosphate | 11 | $14,631 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 19 | $14,491 |
| TradjentaLinagliptin | 25 | $14,080 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Lyumjev, Humalog, Humalog Mix 75-25 | $1,019 | $399,778395 claims |
| Novo NordiskOzempic, Rybelsus | $962 | $244,510231 claims |
| AstraZenecaFarxiga | $512 | $127,365167 claims |
| Boehringer IngelheimJardiance, Tradjenta | $123 | $97,708134 claims |
| AmgenProlia | $60 | $44,70126 claims |
| BayerKerendia | $850 | $32,43840 claims |
| IBSA Pharma Inc.Tirosint-Sol, Tirosint | $126 | $11,38869 claims |
| AbbVieSynthroid | $185 | $7,27791 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $99 | $6,479572 claims |
| Sanofi-aventis U.S. LLCLantus | $384 | $2,36714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Birmingham
- William GarveyBirmingham$3.8M
- Fernando OvalleBirmingham$516K
- Ralph TeagueBirmingham$487K
- Amy WarrinerBirmingham$182K
- Edison GoncalvesBirmingham$142K
- Fernando BrilBirmingham$74K
- Tom VaughanBirmingham$68K
- Rodrigo ValderramaBirmingham$61K
- Janelle TownesBirmingham$56K
- Richard RosenthalBirmingham$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.